{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:10:35Z","timestamp":1790082635356,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019484","name":"Merit Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvir.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jvir.2025.10.018","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T23:06:57Z","timestamp":1761260817000},"page":"107887","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3975-7479","authenticated-orcid":false,"given":"Siddharth A.","family":"Padia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0813-3791","authenticated-orcid":false,"given":"Sachin","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4712-3986","authenticated-orcid":false,"given":"Eric","family":"Wehrenberg-Klee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-5272","authenticated-orcid":false,"given":"Robert D.","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2762-0130","authenticated-orcid":false,"given":"Altan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlana","family":"Orloff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-0825","authenticated-orcid":false,"given":"Hendrik J.F.","family":"Helmerhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Chmielowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-4055","authenticated-orcid":false,"given":"Orhan S.","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5258-291X","authenticated-orcid":false,"given":"Mark C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-187X","authenticated-orcid":false,"given":"Gerd","family":"Gr\u00f6zinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5510-788X","authenticated-orcid":false,"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh P.","family":"Krishnasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2025.10.018_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jvir.2025.10.018_bib2","first-page":"1230","article-title":"Ocular melanoma: an overview of the current status","volume":"6","author":"Jovanovic","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jvir.2025.10.018_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/09286580600553330","article-title":"Uveal and conjunctival malignant melanoma in Denmark 1943-97: observed and relative survival of patients followed through 2002","volume":"13","author":"Isager","year":"2006","journal-title":"Ophthal Epidemiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib4","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2025.10.018_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","article-title":"Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies","volume":"39","author":"Burgmans","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261939","article-title":"Prospective evaluation of percutaneous hepatic perfusion with melphalan as a treatment for unresectable liver metastases from colorectal cancer","volume":"17","author":"Meijer","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2025.10.018_bib7","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","article-title":"Prospective clinical and pharmacological evaluation of the Delcath System's second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan","volume":"40","author":"de Leede","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1055\/s-0040-1720948","article-title":"Locoregional therapies for the treatment of uveal melanoma hepatic metastases","volume":"37","author":"Gonsalves","year":"2020","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jvir.2014.11.037","article-title":"Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases","volume":"26","author":"Valsecchi","year":"2015","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib10","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.14.14001","article-title":"Uveal melanoma metastatic to the liver: chemoembolization with 1,3-bis-(2-chloroethyl)-1-nitrosourea","volume":"205","author":"Gonsalves","year":"2015","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2025.10.018_bib11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1148\/radiol.2019190199","article-title":"A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis","volume":"293","author":"Gonsalves","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2025.10.018_bib12","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3390\/cancers15204942","article-title":"Selective internal radiotherapy (SIRT) and chemosaturation percutaneous hepatic perfusion (CS-PHP) for metastasized uveal melanoma: a retrospective comparative study","volume":"15","author":"Kolb","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2025.10.018_bib13","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","article-title":"Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: results from an open-label, single-arm, multicenter phase 3 study","volume":"31","author":"Zager","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2025.10.018_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","article-title":"Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study","volume":"28","author":"Meijer","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2025.10.018_bib15","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00270-022-03225-9","article-title":"Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis","volume":"45","author":"Tong","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CMR.0000000000000806","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma","volume":"32","author":"Modi","year":"2022","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jvir.2025.10.018_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers14010118","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience","volume":"14","author":"Dewald","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2025.10.018_bib18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/02841851211019808","article-title":"Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma","volume":"63","author":"Estler","year":"2022","journal-title":"Acta Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib19","article-title":"Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan-long-term overall survival negatively correlates with tumor burden","volume":"2020","author":"Br\u00fcning","year":"2020","journal-title":"Radiol Res Pract"},{"key":"10.1016\/j.jvir.2025.10.018_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","article-title":"Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience","volume":"19","author":"Artzner","year":"2019","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.jvir.2025.10.018_bib21","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.24956","article-title":"Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease","volume":"117","author":"Karydis","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jvir.2025.10.018_bib22","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","article-title":"Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study","volume":"40","author":"Vogl","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102501","article-title":"Chemosaturation for primary and secondary liver malignancies: a comprehensive update of current evidence","volume":"113","author":"Vogel","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jvir.2025.10.018_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","article-title":"Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib Part of the Chopin trial","volume":"46","author":"Tong","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12880-022-00887-2","article-title":"Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience","volume":"22","author":"Ebel","year":"2022","journal-title":"BMC Med Imaging"},{"key":"10.1016\/j.jvir.2025.10.018_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254817","article-title":"Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"16","author":"Struck","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jvir.2025.10.018_bib27","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1053\/j.jvca.2025.03.024","article-title":"Anesthesia-specific protocol for percutaneous hepatic perfusion procedures","volume":"39","author":"Nahrwold","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.jvir.2025.10.018_bib28","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241246898","article-title":"Troponin elevation in patients undergoing percutaneous hepatic perfusion for metastatic uveal melanoma","volume":"31","author":"Chandrasekhar","year":"2024","journal-title":"Cancer Control"},{"key":"10.1016\/j.jvir.2025.10.018_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40644-023-00590-7","article-title":"Heparin reversal with protamine sulfate after percutaneous hepatic perfusion (PHP): is less more?","volume":"23","author":"Facchetti","year":"2023","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.jvir.2025.10.018_bib30","article-title":"Initiation of chemosaturation with percutaneous hepatic perfusion program in interventional radiology department","volume":"13","author":"Ocal","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.jvir.2025.10.018_bib31","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00270-024-03713-0","article-title":"Quality of life analysis of patients treated with percutaneous hepatic perfusion for uveal melanoma liver metastases","volume":"47","author":"Tong","year":"2024","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/CMR.0000000000000947","article-title":"Quality of life after melphalan percutaneous hepatic perfusion for patients with metastatic uveal melanoma","volume":"34","author":"Vigneswaran","year":"2024","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jvir.2025.10.018_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/cancers14010118","article-title":"Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the German experience","volume":"14","author":"Dewald","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jvir.2025.10.018_bib35","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","article-title":"Prospective clinical and pharmacological evaluation of the Delcath System's second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan","volume":"40","author":"de Leede","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2025.10.018_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254817","article-title":"Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery","volume":"16","author":"Struck","year":"2021","journal-title":"PLoS One"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044325006888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044325006888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T08:41:37Z","timestamp":1767343297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044325006888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1051044325006888"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2025.10.018","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Liver Metastases from Uveal Melanoma with Percutaneous Hepatic Perfusion","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvir.2025.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 SIR 2025 .","name":"copyright","label":"Copyright"}],"article-number":"107887"}}